A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML

The response rate of non-M3 AML to all trans retinoic acid (ATRA) has been limited. Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA. We therefore per...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Welch, John S., Niu, Haixia, Uy, Geoffrey L., Westervelt, Peter, Abboud, Camille N., Vij, Ravi, Stockerl-Goldstein, Keith E., Jacoby, Meagan, Pusic, Iskra, Schroeder, Mark A., Dipersio, John F., Cashen, Amanda F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4108244/
https://ncbi.nlm.nih.gov/pubmed/24723466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23735
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados